OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!



Risk Factors and Outcomes for Chemotherapy Refusal

(June 7, 2016) The Journal of the National Comprehensive Cancer Network recently published a study that looked at the difference in outcomes between two groups of epithelial ovarian cancer patients: those who received recommended, multiagent chemotherapy and those who chose not to undergo the recommended... 

The Impact of BMI on IP Therapy

(May 25, 2016) A new study published in the International Journal of Gynecological Cancer earlier this month investigated the impact of body mass index (BMI) on completion, complications, and clinical outcomes of intraperitoneal (IP) chemotherapy in patients with advanced-stage ovarian cancer. The study... 

OCRFA Research Helps Explain Resistance to Chemotherapy

Weiping Zou, MD, PhD (May 4, 2016) Research funded in part by an OCRFA research grant to Dr. Weiping Zou at the University of Michigan has shown that the sensitivity and resistance to cancer chemotherapies is not fully explained by genomic mechanisms as it has previously thought.  In fact, it may be...